Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts. Click Here for more Sierra Natl BK Tehachapi Calif (MM) Charts.](/p.php?pid=staticchart&s=N%5ESIRT&p=8&t=15)
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs to
treat diseases of aging such as Type 2 Diabetes, announced today the
completion of its initial public offering of 6,900,000 shares of common
stock, which included 900,000 shares sold pursuant to the underwriters'
exercise in full of their over-allotment option. All shares were sold at
an initial public offering price of $10.00 per share, resulting in
aggregate net proceeds to Sirtris of approximately $62.4 million after
deducting underwriting discounts and commissions and estimated offering
expenses.
J.P. Morgan Securities Inc. acted as the sole book-running manager and
CIBC World Markets Corp., Piper Jaffray & Co., JMP Securities LLC, and
Rodman & Renshaw, LLC acted as co-managers for the offering.
A registration statement relating to these securities was declared
effective by the Securities and Exchange Commission on May 22nd,
2007. The public offering is being made by means of a written
prospectus. Copies of the final prospectus relating to the offering may
be obtained from: J.P. Morgan Securities Inc., Attention: Prospectus
Department, 4 Chase Metrotech Center, CS Level, Brooklyn, NY 11245.
Phone: (718) 242-8002. Email: addressing.services@jpmorgan.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state in which such offer, solicitation or sale would
be unlawful prior to their registration or qualification under the
securities laws of any such state.
About Sirtris Pharmaceuticals
Sirtris Pharmaceuticals is a biopharmaceutical company focused on
discovering and developing proprietary, orally available, small molecule
drugs with the potential to treat diseases associated with aging,
including metabolic diseases such as Type 2 Diabetes. Our drug
candidates are designed to mimic certain beneficial health effects of
calorie restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes. The
company's headquarters are in Cambridge, Massachusetts.